The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, Express Scripts, MedImpact Healthcare Systems and Navitus Health Solutions, th

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

Health insurer Cigna's unit Evernorth Health said on Wednesday it will make changes to help lower out-of-pocket cost of prescription drugs for patients at its pharmacy stores. The changes will protect patients from paying a high list price for their medication by giving them access to lower prices negotiated by Cigna's pharmacy benefit manager,

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

As PBM services have traditionally been dominated by large companies such as CVS Caremark, Express Scripts and OptumRx, health systems are starting to create alternatives. Here are four more things to know:

As the rising cost of insulin continues to make it difficult for so many diabetic patients to receive life-saving care, Insulin Outlet is stepping up to help by providing safe, affordable, and accessible insulin to those who need it most.

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country’s first trade surplus in energy since at least the 1950s.

Independent drugstores are closing at an alarming rate, squeezed by the huge companies that reimburse pharmacies for costly medications.

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,